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AbstrAct
CD137 (4- 1BB) is a surface glycoprotein that belongs to 
the tumour necrosis factor receptor family (TNFRSF9). 
Its expression is induced on activation on a number of 
leucocyte types. Interestingly, for cancer immunotherapy, 
CD137 becomes expressed on primed T and natural 
killer (NK) cells, which on ligation provides powerful 
costimulatory signals. Perturbation of CD137 by CD137L 
or agonist monoclonal antibodies on activated CD8 T cells 
protects such antigen- specific cytotoxic T lymphocytes 
from apoptosis, enhances effector functionalities and 
favours persistence and memory differentiation. As a 
consequence, agonist antibodies exert potent antitumour 
effects in mouse models and the CD137 signalling 
domain is critical in chimeric antigen receptors (CAR) 
of CAR T cells approved to be used in the clinic. New 
formats of CD137 agonist moieties are being clinically 
developed, seeking potent costimulation targeted to the 
tumour microenvironment to avoid liver inflammation side 
effects, that have thus far limited and delayed clinical 
development.
IntroduCtIon
Cancer immunotherapy is already an impor-
tant pillar in oncology treatments. T cells 
are the main mediators of efficacy. These 
immune cell subsets can specifically recog-
nise tumour cells and kill them when prop-
erly activated. The understanding of the 
underlying biological processes that deter-
mine T- cell fate on activation in the tumour 
microenvironment (TME) represents one 
of the main cornerstones for the future of 
cancer immunotherapy. Enabling immune 
responses by targeting immune inhibitory 
signals (immune checkpoints) using PD-1/
PD- L1 and/or CTLA-4 blockers has shown 
remarkable clinical efficacy against a large 
number of malignancies, but responses are 
still limited to a small fraction of patients.1 
In parallel with T- cell inhibition blockade, 
immune cell stimulation by agonistic agents 
acting on costimulatory receptors such as 
CD137, OX40, TNFR2, CD27, CD40 or GITR, 
which are mainly expressed on T cells, consti-
tute an area of very active preclinical and clin-
ical research.
Cd137 bIologICal baCkground
CD137/4- 1BB (tnfrsf9) is a costimulatory 
receptor and a member of the tumour necrosis 
factor receptor superfamily (TNFRSF) that 
was initially discovered on activated T cells.2 
CD137 is transiently expressed on activated T 
cells that have encountered cognate antigen, 
activated NK cells or mature dendritic cells 
(DCs). To date, a unique functional ligand 
has been identified for CD137, CD137L/4- 
1BBL (tnfsf9), expressed on the surface of 
professional antigen- presenting cells such as 
DCs, macrophages and B cells.3 Structurally, 
no enzymatic activity has been described for 
the intracellular domain of CD137 which is 
believed to function by recruiting TRAF1, 
TRAF2 and maybe TRAF3 adaptor proteins 
that mediate K63 polyubiquitination reac-
tions in the CD137 signalosome.4 CD137L 
trimerisation leads to CD137 receptor clus-
tering and TRAFs- mediated activation of 
NF-κB and MAPK intracellular signalling 
cascades, ultimately leading to cell activa-
tion, proliferation and survival.5 Bcl- XL, Bfl-1 
induction and downregulation of BIM have 
been identified as antiapoptotic mechanisms, 
that seems to involve a role for interference 
with activation- induced cell death.6
On T cells, T cell receptor (TCR) stimula-
tion and subsequent CD3 signalling induce 
transient expression of CD137 that on liga-
tion with agonist antibodies or the natural 
ligand probably favours Th1 responses. Of 
note, CD28 costimulation results in mark-
edly enhanced CD137 surface expression.7 
Initial reports using CD137 monoclonal anti-
bodies (mAbs) in mouse and human cells 
demonstrated that CD137 ligation causes 
strong costimulatory signals in T cells that in 
cooperation with TCR signalling gives rise to 
interleukin (IL)-2 and interferon ɣ (IFN-ɣ) 
production as well as T- cell proliferation.8 
Further studies have shown that, in addition 
to inducing effector cytokine production, 
CD137 costimulation favours T cell memory 
and effector differentiation,5 protects T cells 
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Figure 1 Schematic representation of a tumour- infiltrating T lymphocyte expressing CD137 as a result of priming by tumour- 
antigen recognition. Then, novel strategies to make the most of CD137 costimulation are represented including bispecifics and 
direct intratumour injections. FAP, fibroblast activation protein; mAb, monoclonal antibody.
from apoptosis,6 changes the mitochondrial metabolism 
to increase T- cell respiratory capacities9 10 and induces 
overall DNA demethylation and chromatin reprogram-
ming.11 In tumour models, in vitro and in vivo studies 
point towards a principal role of CD137 in CD8+ T cells 
rather than in CD4+ T cells, even though CD137 is induc-
ible on both CD8+ and CD4+ T cells, including CD4+ 
FoxP3+ regulatory T cells (Tregs).12 Of note, the func-
tional role of CD137 signalling on Th1 CD4+ and Tregs is 
still poorly understood and it may not be as physiologically 
relevant as for CD8+ T cells. On activated NK cells, CD137 
triggering results in increased cell activation.13 Reports 
on enhancement of antibody- dependent cell cytotoxicity 
and cytotoxic functions have been retracted,14 15 but there 
is evidence that it contributes to NK activation.16
Because of (1) the strong costimulatory activity on cyto-
toxic T cells that boosts cell proliferation and survival, (2) 
the specific expression on antigen- primed tumour- specific 
T cells in the TME and draining lymph nodes17 18 and 
(3) the sustained signalling over time causing long- term 
changes in tumour- specific T cells,19 CD137 is considered 
an attractive target to enhance cancer immunotherapy. 
Furthermore, recent evidence on CD137 expression on 
CD4+ FoxP3+ Tregs indicated that CD137 can be used as 
a target to reduce/deplete Tregs which more brightly 
express CD137 and thereby offer a window for selective 
depletion.12
Cd137-based CanCer Immunotherapy In preClInICal 
models
The first in vivo evidence for the therapeutic potential of 
CD137 targeting in cancer was shown in transplantable 
tumour models of sarcoma and mastocytoma in which 
CD8+ T cell- dependent complete tumour eradication was 
attained using agonistic anti- CD137 mAbs.20 Ever since, 
accumulating preclinical data support the antitumour 
activity of CD137 agonism in several immunogenic and 
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doses of ≥1 mg/
kg
  B- cell non- Hodgkin’s 
lymphoma
I (completed) NCT01775631




I and II (not 
recruiting)
NCT03792724
        Solid tumours and 
B- cell non- Hodgkin’s 
lymphoma
I and II 
(completed)
NCT02253992
        Muscle- invasive 
urothelial carcinoma of 
the bladder (neadjuvant 
nivolumab)
II (recruting) NCT02845323
        Advanced and/or 
metastatic malignant 
tumours
I (active, not 
recruiting)
NCT02534506
        Multiple metastases in 
advanced solid tumours
I (recruiting) NCT03431948
        Recurrent globlastoma I (active) NCT02658981





I and II 
(recruiting)
NCT02451982
        Tumour- 
infiltrating 
lymphocytes
Metastatic melanoma I (active, not 
recruiting)
NCT02652455





      Elotuzumab (anti- 
CS1)
Multiple myeloma I (completed) NCT02252263
      Ipilumumab
(anti- CTLA-4)










Advanced solid tumours I (completed) NCT02179918
  Ligand 
blocking




Advanced solid tumours I (terminated) NCT02444793
      Rituxumab
(anti- CD20)
Solid tumours or B- cell 
lymphomas
I (completed) NCT01307267





      Trastuzumab
(anti- HER2)
Advanced HER2- positive 
breast cancer
I (recruiting) NCT03364348
        Avelumab
(anti- PD- L1)
Advanced HER2 +breast 
cancer
II (recruting) NCT03414658
      Avelumab
(anti- PD- L1)
Triple negative breast 
cancer
II (recruiting) NCT03971409
        Locally advanced or 
metastatic solid tumours
II (recruiting) NCT02554812
        PF-8600 (OX-
40 agonist)
Advanced solid tumours I and II 
(recruiting)
NCT03217747
        Rituximab
(anti- CD20)
Relapsed or refractory 














agent Condition Phase NCT
        Rituximab
(anti- CD20)
Relapsed or refractory 
diffuse large B- cell 
lymphoma or mantle cell 
lymphoma
I (recruiting) NCT03440567
      PF-8600 (OX-40 
agonist)
Advanced or metastatic 
carcinoma
I (active, not 
recruiting)
NCT02315066





II (active, not 
recruiting)
NCT03258008
      Primed CD8 
+tumour antigen- 
specific T cells
Aldesleukin Recurrent ovarian cancer I (recruiting) NCT03318900
Table 1 Continued
non- immunogenic tumour models. These same tumour 
models have been crucial for the understanding of the 
mechanistic principles behind CD137 costimulation 
in cancer. Among them, it has been shown that CD137 
agonists could prevent cytotoxic T lymphocyte (CTL) 
anergy and thereby break T cell tolerance towards tumour 
antigens,21 restore T cell dysfunctionality in the TME22 
and increase persistence of tumour- specific T cells.23
On their way to the preclinical development of CD137 
agonists, initial efforts were made to force expression of 
CD137L on poorly immunogenic sarcoma cells7 or the 
prostate- specific membrane antigen (PSMA) recognising 
T cells,24 this strategy resulted in increased immunoge-
nicity and enhanced antitumour activity. However, studies 
using agonistic mAbs showed stronger antitumour activity 
probably because of stronger agonistic actions and thus 
became the focus of translational research. Similar to 
other TNFRSF agonists such as CD40 mAbs, the road to 
the development of sufficiently agonistic CD137 has not 
been straightforward. In order to attain functional CD137 
signalling and costimulation, agonist CD137 mAb must 
trimerise the receptor, a feature that requires effective 
crosslinking of the Fc to FcɣRs. In line with this, Buchan 
et al suggested a sequential mAb treatment scheme using 
a dual Fc engineering strategy to make the most of the 
CD137- specific expression pattern, first treating with an 
activating FcɣRs- binding mIgG2a mAb to deplete intra-
tumour Tregs brightly expressing CD137, followed by an 
inhibitory FcɣRs- binding mIgG1 mAb to provide strong 
costimulation to CD8 CTLs.25
Along with the efficacy of anti- CD137 antibody as a 
monotherapy, a broad number of synergistic combina-
tions have been reported. Checkpoint inhibitory recep-
tors such as PD-1 or CTLA-4 are commonly found to 
be upregulated in dysfunctional T cells within the TME 
across multiple types of malignant diseases.1 Checkpoint 
receptors on binding their ligands repress T- cell activation 
intracellular signals that had frequently been induced 
by costimulatory receptors. To make the most of these 
facts, simultaneous blockade of checkpoint inhibitor 
receptors in conjunction with agonistic mAbs triggering 
costimulatory receptors makes sense26. This can be 
achieved also with bispecific antibodies encompassing 
both activities in a single moiety. In this regard, true syner-
gistic combinations are a major goal in cancer immu-
notherapy.27 CD137- resistant ovarian and lung cancer 
models become amenable to eradication on combined 
treatment with anti- CD137 mAb with PD-1 blocking mAb, 
resulting in potent synergistic effects that correlate with 
increased T- cell survival and effector functions.28 Inter-
estingly, CD137 and PD-1 coexpression is likely to be 
restricted to neoantigen- specific tumour- infiltrating CD8+ 
T cells,29 suggesting the rational of combining both path-
ways for immunotherapeutic purposes. Combination of 
CTLA-4 blocking mAb with anti- CD137 mAb also resulted 
in enhanced CD8+ T- cell mediated immune responses in 
mouse models of melanoma.30 In addition to checkpoint 
blockade, combination with immunostimulatory mAbs 
such as CD40,31 OX4032 or CD2033 has been reported to 
potentiate the antitumour effects.
Other therapeutic strategies including radiotherapy,34 
gene therapy35 or adoptive cell therapy synergise with 
CD137 stimulation. Combination of CD137 mAb with 
adoptive T cell therapy in mouse models of B16OVA 
and OVA- specific CD8+ T cell (OT1) transfer resulted in 
long- lasting tumour control elicited by enhanced effector 
functions of the transferred and endogenous CD8+ T cells 
that when visualised by intravital microscopy behaved 
more aggressively against malignant cells.23
Cd137 Immunotherapy In ClInICal development
Two approaches encompassing CD137 have been eval-
uated in the clinic: (1) anti- CD137- targeting mAbs and 
bispecific Abs and (2) the cytoplasmatic CD137 domain 
forming part of chimeric antigen receptors (CAR). Today, 
CD19 targeting CAR- T cells are the only CD137- based 
approach approved by the FDA for the treatment of B- cell 
paediatric leukaemia and refractory B- cell lymphoma.36 
In contrast to CD28 encompassing CARs, CD137 intracel-
lular signalling domain- based CARs are those achieving 
best adoptive T- cell persistence.37 In addition, stronger 
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metabolic fitness and beneficial epigenetic reprograming 
have been associated with CD137 containing CARs.38
Two agonist anti- CD137 mAb have been tested in the 
clinical setting; urelumab (BMS-663513), a fully human 
IgG4- based anti- CD137 mAb that does not block CD137L–
CD137 interactions and utolimumab (PF-05082566), a 
ligand- blocking- humanised IgG1 mAb (table 1).
Initial reports testing urelumab in phase I and II 
trials showed activity as a single agent in patients with 
advanced cancer, but trials had to be terminated because 
of treatment- related severe adverse effects in the form of 
liver inflammation.39 The hepatotoxicity observed in the 
patients had not been observed in non- human primates 
due to lower binding affinities to cynomolgus CD137. 
An integrated safety analysis of urelumab revealed life- 
threating liver inflammation associated with doses of 
≥1 mg/kg that required a drastic dose reduction to 0.1 mg/
kg to be safe.40 Such dose reduction maintained little 
pharmacodynamic activity and resulted in loss of efficacy 
as monotherapy except for a few B- cell non- Hodgkin’s 
lymphoma cases, where some objective responses were 
observed. Despite the dose reduction requirement, the 
obtained safety prolife supported evaluation of urelumab 
in combination with other immune- modulating agents. 
Low doses of urelumab in combination with the anti- PD1 
mAb nivolumab showed acceptable tolerability and prom-
ising clinical responses have been reported in patients 
with metastatic melanoma irrespective of PD- L1 tumour 
expression.41 Urelumab is further being combined with 
cetuximab (NCT02110082), rituximab (NCT01775631) 
and elotuzumab (NCT02252263) (table 1).
On the contrary, utolimumab has no dose- limiting 
toxicities and shows preliminary antitumour activity in 
patients with advanced cancer. Probably because of being 
a weak CD137- agonist, utolimumab has shown little clin-
ical effect as a monotherapy.42 Phase 1 combination strat-
egies combining utolimumab with rituximab in patients 
with relapsed or refractory non- Hodgkin’s lymphoma43 
and utilimumab with pembrolizumab in patients with 
advanced solid tumours44 have demonstrated tolera-
bility, safety and preliminary clinical activity. Another 
combinatorial strategy being tested is the combination of 
utomilumab with intravenous infusion of CD8 +tumour 
antigen- specific T cells (NCT03318900; table 1).
CD137 mAb therapy aims to stimulating the activity of 
tumour- specific T cells already within the TME. Tumour 
susceptibility to the mAb treatment is likely to depend on a 
pre- existing tumour T- cell infiltration and on CD137 expres-
sion levels on such tumour- infiltrating T cells. For clinical 
purposes, well- defined prognostic and predictive markers 
for CD137 treatment are still missing. Thus, biomarker 
discovery and validation for CD137- based immunothera-
pies currently constitute a major research effort.
lessons learnt: movIng Cd137 agonIsts towards safer 
tumour targetIng
Preclinical studies trying to elucidate the hepatotoxicity 
related to CD137 agonists showed hepatic polyclonal CD8+ 
T cell activation and IFN-ɣ secretion as the main media-
tors of liver damage.45 Further studies link CD137 mAb 
binding to liver resident monocyte and Kupffer cell that 
secrete tumour necrosis factor α (TNF-α) and IL-27 and 
activate CD8+ T cells, ultimately leading to liver damage.46 
Prompted by the preclinical mechanistic insight and based 
on the clinical experiences using CD137 mAb, that when 
sufficiently agonistic lead to severe liver inflammation, new 
efforts are in place to specifically bring CD137 agonism to 
the tumour tissue microenvironment (figure 1).
Different approaches are on the table, among them 
the most advanced ones under clinical development are 
the CD137- based bispecific constructs that are designed 
to bring CD137 costimulation specifically to the TME. 
A bispecific antibody targeting CD137 on T cells and 
the oncogenic antigen HER2 expressed on tumour cells 
(HER2/4- 1BB Ab) has been the first CD137- based bispecific 
Ab tested in the clinic.47 Recently, results presented from 
the phase 1 single- agent dose escalation trial evaluating 
HER2/4- 1BB Ab in patients with HER2+ solid tumours, 
indicated good tolerability of the construct and showed 
evidence of clinical activity.48 Another tumour targeting 
bispecific construct being explored in the clinic is the 
PD- L1 targeting PD- L1/4- 1BB Ab (NCT03809624). Preclin-
ically, bispecific Ab targeting the tumour antigen 5T4 and 
CD137 (5T4/4- 1BB Ab) has shown promising activity in 
cell cultures.49 In addition, a chimeric protein consisting 
on a trimeric form of CD137L integrated into a fibro-
blast activation protein (FAP), a highly expressed protein 
on the tumour stroma, recognising bispecific construct 
(FAP/4- 1BBL) has shown impressive anti- tumoural activi-
ties against tumour mouse models and tumour- targeting in 
spontaneous cancer bearing rhesus monkeys, with no signs 
of toxicity in macaques.50 In line with the bispecific designs 
and to avoid FcɣR binding mediated liver toxicity, Fc lacking 
trimeric CD137 constructs with sufficient agonistic activity 
and without liver toxicity have been successfully evaluated 
in mouse models.51
Another approach to specifically provide CD137 costim-
ulation to the TME includes intratumour injections of low 
doses of the CD137 mAb.52 Following preclinical evidence 
demonstrating the feasibility and antitumour efficacy of the 
intratumour administration, a clinical trial injecting low 
doses of CD137 mAb directly into metastatic lesions and in 
combination with systemic nivolumab is being conducted 
in patients with solid tumours (NCT03792724).
ConClusIon
The immunobiology of CD137 provides the basis for our 
understanding of the role of CD137 costimulation in cancer 
and arguably presents CD137 as one of the most potent 
costimulatory receptors for primed CD8+ T cells. Preclinical 
data convincingly show strong antitumour activity of CD137 
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agonists. Consequently, CD137 emerges as a robust candi-
date to be targeted for cancer treatment. The beginnings 
of CD137 agonist mAb in the clinic were overshadowed by 
hepatic toxicities in a not well- defined fraction of patients. 
In spite of such caveats, (1) safe combinatorial strategies, 
involving checkpoint inhibitors and CD137 agonists, 
designed to simultaneously normalise and stimulate the 
inhibited antitumour immune responses or (2) strategies 
to specifically target CD137 agonists to the TME are likely 
to broaden the therapeutic window. In the next years, we 
need to harness a promising foal to turn it into a powerful 
warhorse against cancer.
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